Listed by the USPTO as SULLIVAN, DENNIS JOHN
Tech Center 1600 • Art Units: 1642 1646 1674
This examiner grants 58% of resolved cases
SULLIVAN, DENNIS JOHN is assigned to tech center 1600 and art unit 1642. The record includes 119 resolved cases, with an allowance rate of 58.0%, interview lift of 48.3%, and a median of 1364 days to allowance. The profile combines a moderate allowance outcome with a strong recorded association between interviews and allowance.
The top companies are Janssen Pharmaceuticals Inc., The Regents of the University of California, and University of Florida Research Foundation Inc. The top firms are BakerHostetler, COOLEY LLP, and ArentFox Schiff, LLP & Memorial Sloan-Kettering. Practitioners may want to prioritize interview preparation where the issues can be narrowed through examiner discussion. The median duration is lengthy, so interview planning should be integrated early rather than reserved for the end of prosecution.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18038321 | USE OF INSULIN-LIKE GROWTH FACTORS WITH GAMMA-CHAIN CYTOKINES TO INDUCE HOMEOSTATIC PROLIFERATION OF LYMPHOCYTES | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED |
| 17769171 | COMPOSITIONS AND METHODS FOR DETECTING PLXDC1 AND PLXDC2 IN HUMAN TISSUES | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17286083 | Methods to Diagnose and Treat Cancer Using Non-Human Nucleic Acids | Final Rejection | The Regents of the University of California |
| 18216026 | Use of Anti-EGFR/Anti-Met Antibody to Treat Gastric or Esophageal Cancer | Non-Final OA | Janssen Biotech, Inc. |
| 18300183 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone | Non-Final OA | Janssen Biotech, Inc. |
| 18300288 | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone | Non-Final OA | Janssen Biotech, Inc. |
| 18565023 | COMPOSITIONS AND METHODS TO TRANSFECT, TEST, AND TREAT SKIN CELLS | Non-Final OA | The Regents of the University of Michigan |
| 18556488 | THE IMMUNOMODULATORY LIGAND B7-1 MEDIATES SYNAPTIC REMODELING BY P75NTR | Final Rejection | Cornell University |
| 18020515 | PLASMA EXCHANGE REMOVAL OF SPD-L1 | Final Rejection | Mayo Foundation for Medical Education and Research |
| 19243836 | SUBCUTANEOUS FCRN ANTAGONIST FORMULATIONS AND METHODS OF USE THEREOF | Non-Final OA | argenx BV |
| 17517567 | USE OF ISATUXIMAB FOR THE TREATMENT OF MULTIPLE MYELOMA | Final Rejection | Sanofi-Aventis U.S. LLC |
| 17797916 | COMPOSITION COMPRISING CHEMOKINE INHIBITOR, COLONY STIMULATING FACTOR INHIBITOR, AND CANCER IMMUNOTHERAPY AGENT FOR PREVENTION OR TREATMENT OF CANCER AND COMBINATION THERAPY | Non-Final OA | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 17909310 | ANTI-CCR8 AGENTS | Final Rejection | Memorial Sloan Kettering Cancer Center |
| 18280981 | USE OF OREGOVOMAB AND BEVACIZUMAB, PACLITAXEL, CARBOPLATIN FOR TREATMENT OF BRCA-WILD TYPE PLATINUM SENSITIVE RECURRENT | Non-Final OA | CANARIABIO INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy58.0% of resolved applications examined by Dennis John Sullivan were allowed (119 resolved cases), compared with 38.5% across Art Unit 1642 over the last five years.
This examiner's interview lift is +48.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Dennis John Sullivan took 1,364 days on average from filing to allowance.
Dennis John Sullivan examines applications in Art Unit 1642 in Tech Center 1600 (Biotechnology & Pharmaceuticals).